 The presence of the BCR/ABL1 fusion gene in childhood acute lymphoblastic leukaemia (ALL) is a rare finding and has been an adverse prognostic factor associated with a high risk of therapeutic failure.     ///    The current key components of treatment are intensive polychemotherapy and a BCR/ABL1 kinase domain inhibitor. 